Core Insights - The company is advancing its AI strategy by launching an AI-driven research platform focused on PROTAC mechanisms, which enhances the rational design of lead compounds and clinical translation through a comprehensive data foundation [1][2] Group 1: AI Strategy and Platform Development - The AI platform aims to create a high-quality, structured PROTAC-specific database (HEC-PROTACDB) that integrates molecular structures, degradation activities, physicochemical properties, and pharmacokinetic parameters from clinical pipelines, patents, and literature [2] - The database currently includes over 30,000 PROTAC molecules, more than 500 POI ligands, over 1,000 types of linkers, 200 E3 ligands, and more than 150 targets, significantly surpassing existing public databases in data scale and structural granularity [2] Group 2: Drug Development and Collaborations - The company is enhancing its AI drug development strategy through collaborations with industry leaders such as Beijing DeepTech and Huawei Cloud, establishing six proprietary models that cover the entire drug discovery process from molecular design to prescription design [3] - The first AI-driven small molecule drug, HEC169584, targeting metabolic-associated fatty liver disease (MASH), has entered clinical phase I, showing high in vitro activity against THR-β cells and strong liver targeting, with reduced impact on the thyroid axis and heart [3]